Correa Sebastião Francisco Miranda, Marta Gustavo Nader, Teixeira Manoel Jacobsen
Radiation Oncology Department - Hospital Sírio-Libanês, Rua Dona Adma Jafet, 91 - Bela Vista, CEP 01308-050 Sao Paulo, SP, Brazil.
Radiat Oncol. 2014 Jan 17;9:27. doi: 10.1186/1748-717X-9-27.
The tumor removal of Cavernous Sinus Meningiomas usually results in severe neurological deficits. Stereotactic radiosurgery (SRS) and fractionated Stereotactic radiotherapy (SRT) are advanced modalities of radiotherapy for treatment of patients with inoperable and symptomatic CSMs. The authors evaluated the long term symptomatology, the image findings, and the toxicity of patients with CSMs treated with SRS or SRT.
From 1994 to 2009, 89 patients with symptomatic CSMs were treated with SRS or SRT. The indication was based on tumour volume and or proximity to the optic chiasm. The median single dose of SRS was 14 Gy, while the SRT total dose, ranged from 50.4 to 54 Gy fractionated in 1.8-2 Gy/dose. The median follow-up period lasted 73 months.
The clinical and radiological improvement was the same despite the method of radiotherapy; 41.6% (SRS) and 48.3% (SRT) of patients treated. The disease-free survivals were 98.8%, 92.3% and 92.3%, in 5, 10, and 15 years, respectively. There was no statistical difference in relation to the symptoms and image findings between both methods. According to the Common Toxicity Criteria, 7% of the patients presented transient optic neuropathy during 3 months (grade 2) and recovered with dexamethasone, 2 patients had trigeminal neuropathy (grade 2) and improved rapidly, and one patient presented total occlusion of the internal carotid artery without neurological deficit (grade 2). Temporary lethargy and headache (grade 1) were the most frequent immediate complications. No severe complications occurred.
Stereotactic Radiosurgery and fractionated Stereotactic Radiotherapy were equally safe and effective in the management of symptomatic CSMs.
海绵窦脑膜瘤的肿瘤切除通常会导致严重的神经功能缺损。立体定向放射外科(SRS)和分次立体定向放射治疗(SRT)是治疗无法手术且有症状的海绵窦脑膜瘤患者的先进放射治疗方式。作者评估了接受SRS或SRT治疗的海绵窦脑膜瘤患者的长期症状、影像学表现及毒性。
1994年至2009年,89例有症状的海绵窦脑膜瘤患者接受了SRS或SRT治疗。治疗指征基于肿瘤体积和/或与视交叉的距离。SRS的中位单次剂量为14 Gy,而SRT的总剂量为50.4至54 Gy,分1.8 - 2 Gy/次给予。中位随访期为73个月。
无论采用何种放射治疗方法,临床和影像学改善情况相同;接受治疗的患者中,SRS组为41.6%,SRT组为48.3%。5年、10年和15年的无病生存率分别为98.8%、92.3%和92.3%。两种方法在症状和影像学表现方面无统计学差异。根据常见毒性标准,7%的患者在3个月内出现短暂性视神经病变(2级),用地塞米松治疗后恢复;2例患者出现三叉神经病变(2级)且迅速改善;1例患者出现颈内动脉完全闭塞但无神经功能缺损(2级)。最常见的即刻并发症是短暂性嗜睡和头痛(1级)。未发生严重并发症。
立体定向放射外科和分次立体定向放射治疗在有症状的海绵窦脑膜瘤治疗中同样安全有效。